BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: bioatla.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 11/13/2024 | Buy → Neutral | H.C. Wainwright | |
| 9/15/2022 | $17.00 | Mkt Outperform | JMP Securities |
| 5/5/2022 | $35.00 → $5.00 | Outperform → Neutral | Credit Suisse |
| 3/21/2022 | $25.00 | Buy | H.C. Wainwright |
| 10/15/2021 | $68.00 | Buy | BTIG Research |
| 6/28/2021 | $75.00 | Buy | ROTH Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
10-Q - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)
8-K - BioAtla, Inc. (0001826892) (Filer)
424B3 - BioAtla, Inc. (0001826892) (Filer)
EFFECT - BioAtla, Inc. (0001826892) (Filer)
S-3 - BioAtla, Inc. (0001826892) (Filer)
10-Q - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citizens JMP downgraded BioAtla from Mkt Outperform to Mkt Perform
H.C. Wainwright downgraded BioAtla from Buy to Neutral
JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00
Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously
H.C. Wainwright initiated coverage of BioAtla with a rating of Buy and set a new price target of $25.00
BTIG Research resumed coverage of BioAtla with a rating of Buy and set a new price target of $68.00
ROTH Capital initiated coverage of BioAtla with a rating of Buy and set a new price target of $75.00
Credit Suisse resumed coverage of BioAtla with a rating of Outperform and set a new price target of $68.00
Credit Suisse resumed coverage of BioAtla with a rating of Outperform and set a new price target of $68.00
BTIG reiterated coverage of BioAtla with a rating of Buy and set a new price target of $87.00 from $47.00 previously
Fastest customizable press release news feed in the world
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of so
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and Webcast Information Date: Thursday, August 7, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (internation
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company" or "BioAtla"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced an oral presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting to be held in Hong Kong Sar, China from July 18–20, 2025. Oral Presentation Details: Title: First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinomaAuthors: Jennifer B.
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company" or "BioAtla"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented first-in-human data in a poster titled "Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, "Phase
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place Convention Center in Chicago, IL from April 25–30, 2025. Two abstracts accepted for poster presentation highlight Company's proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfor
Live Leadership Updates
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board. Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti
Live finance-specific insights
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and Webcast Information Date: Thursday, August 7, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (internation
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call and Webcast Information Date: Thursday, March 27, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domes
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all eight, first-line unresectable or metastatic melanoma patients with 4 responses including a complete response (CR), ongoing, with relatively low incidence and severity of immune-related adverse events;
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 7, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 343-4136 (domestic), (203) 518-9848 (internationa
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in NSCLC showed trend for improved overall survival among treated patients with tumors expressing mutated KRAS variants compared to KRAS wildtype; anti-tumor activity across multiple KR
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 8, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, August 8, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 579-2543 (domestic), (785) 424-1789 (international)C
This live feed shows all institutional transactions in real time.
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G - BioAtla, Inc. (0001826892) (Subject)